NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, ...
With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results